Searched for
MANKIND PHARMA QUARTERLY EARNINGS
Ahead of Market: 10 things that will decide stock market action on TuesdayIndian equities ended lower, snapping a two-day rally as escalating Iran-US tensions and profit booking weighed on sentiment. Sensex fell 3...
Market wrap: Sensex falls 372 points, Nifty closes below 23,950; Kotak Mahindra Bank drops 3%Indian markets ended lower as Sensex and Nifty snapped a two-session winning streak, pressured by geopolitical tensions in the Middle East ...
Q1 earnings preview: Here’s what Nomura expects from Nestle, Titan, other consumer majors’ June quarter resultsNomura expects consumer staples to deliver a strong start to FY27, forecasting double-digit sales growth for several companies in the June ...
Dominant India thrash Pakistan 7-1 in FIH Pro LeagueIndia's men's hockey team delivered a stunning performance, defeating Pakistan 7-1 in the FIH Pro League. After trailing early, India surge...
Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
Oil slide powers India's stock benchmarks to longest weekly winning run 7 monthsIndian stock markets achieved their longest winning streak in seven months, with the Nifty 50 and BSE Sensex closing higher. Falling crude ...
India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
Broader market winners! How investors found 15 multibaggers in a muted Nifty year?Despite a subdued Nifty, several Indian stocks have surged, becoming multibaggers for investors. This outperformance is attributed to resil...
Missed the FII U-turn? 6 stocks turned multibagger after foreign investors corrected their mistakeForeign institutional investors (FIIs) reversed their selling trend in six select Indian stocks, turning them into multibaggers. Bajaj Cons...
Largecaps over midcaps, banks over PSUs: V Srivatsa reveals where smart money is headingIndia's market outlook is positive, driven by cooling geopolitical tensions and falling crude oil prices, according to UTI AMC's V Srivatsa...
Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
Quote of the day by Chuck Akre: "Wall Street has this wonderful business about how to create transactions. They set up what we believe are false expectations, and that’s what I call the “beat by a penny, missed by a penny syndrome.”Chuck Akre criticises Wall Street’s fixation on marginal earnings beats and misses, arguing it fuels short-term trading over meaningful ana...
Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
Smallcap funds beat all equity mutual fund categories over 3 months. Should investors change SIP strategy?Smallcap funds have emerged as the best-performing equity mutual fund category over the last three months, delivering an average return of ...
Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
Christy Mathai used market dip to buy insurance, logistics stocks; here's his sector-by-sector playbookFund Manager Christy Mathai sees easing war-driven inflation fears, expecting a shorter earnings hit. He's selectively adding to his portfo...